Salix shares rise on new data, deals

Shares of Raleigh, NC-based Salix Pharmaceuticals surged about 20 percent this morning after the company announced a trifecta of upbeat developments. New trial data are supporting two of its therapies while Salix also announced a co-promotion deal on an existing drug and the acquisition of another therapy.

A mid-stage study of Xifaxan demonstrated efficacy in treating patients suffering from diarrhea-associated irritable bowel syndrome. And a late-stage study of its granulated mesalamine product demonstrated efficacy in keeping ulcerative colitis in remission. Salix inked a co-promotion pact with Eisai for Colazal.

- here's the report from the Triangle Business Journal

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.